Guoliang Yang1, Lianhua Zhang1, Mengyao Liu2, Qiang Liu3, Xuehui Duan1, Juanjie Bo4. 1. Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 2. Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 3. Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 4. Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. bojuanjie12@126.com.
Abstract
PURPOSE: Macrophages are a major cell type that can infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. This study investigates the prognostic value of tumor-infiltrated CD163+ macrophages in patients with T1 high-grade (T1HG) bladder cancer. METHODS: CD163+ macrophages were assessed by immunohistochemistry in 94 T1HG bladder cancer samples. Kaplan-Meier analyses and Cox proportional hazards' regression models were applied to evaluate recurrence-free survival, progression-free survival and disease-specific survival. RESULTS: With a median follow-up of 60 months, 37 (39.4%) patients experienced disease recurrence, 14 (14.9%) progression, 11 (11.7%) disease-specific mortality. High CD163+ macrophages were associated with higher risk of disease recurrence and progression (P < 0.05, for both). In multivariate Cox proportional hazards regression analysis, high CD163+ macrophages were a significant negative predictor of recurrence-free survival, progression-free survival and disease-specific survival (P < 0.05 for all). CONCLUSION: CD163+ macrophages are a poor prognostic factor in T1HG bladder cancer. This finding provide the ground for further testing it in predicting the outcome of this challenging disease.
PURPOSE: Macrophages are a major cell type that can infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. This study investigates the prognostic value of tumor-infiltrated CD163+ macrophages in patients with T1 high-grade (T1HG) bladder cancer. METHODS:CD163+ macrophages were assessed by immunohistochemistry in 94 T1HG bladder cancer samples. Kaplan-Meier analyses and Cox proportional hazards' regression models were applied to evaluate recurrence-free survival, progression-free survival and disease-specific survival. RESULTS: With a median follow-up of 60 months, 37 (39.4%) patients experienced disease recurrence, 14 (14.9%) progression, 11 (11.7%) disease-specific mortality. High CD163+ macrophages were associated with higher risk of disease recurrence and progression (P < 0.05, for both). In multivariate Cox proportional hazards regression analysis, high CD163+ macrophages were a significant negative predictor of recurrence-free survival, progression-free survival and disease-specific survival (P < 0.05 for all). CONCLUSION:CD163+ macrophages are a poor prognostic factor in T1HG bladder cancer. This finding provide the ground for further testing it in predicting the outcome of this challenging disease.
Entities:
Keywords:
Bladder cancer; CD163+ macrophage; Prognosis; T1 high grade
Authors: Bas W G van Rhijn; Liyang Liu; André N Vis; Peter J Bostrom; Tahlita C M Zuiverloon; Neil E Fleshner; Madelon N M van der Aa; Sultan S Alkhateeb; Chris H Bangma; Michael A S Jewett; Ellen C Zwarthoff; Bharati Bapat; Theo H van der Kwast; Alexandre R Zlotta Journal: BJU Int Date: 2012-03-27 Impact factor: 5.588
Authors: Robert S Svatek; Brent K Hollenbeck; Sten Holmäng; Richard Lee; Simon P Kim; Arnulf Stenzl; Yair Lotan Journal: Eur Urol Date: 2014-01-21 Impact factor: 20.096
Authors: Daniel Canter; Brian Egleston; Yu-Ning Wong; Marc C Smaldone; Jay Simhan; Richard E Greenberg; Robert G Uzzo; Alexander Kutikov Journal: Urol Oncol Date: 2011-09-09 Impact factor: 3.498
Authors: G Comito; E Giannoni; C P Segura; P Barcellos-de-Souza; M R Raspollini; G Baroni; M Lanciotti; S Serni; P Chiarugi Journal: Oncogene Date: 2013-06-03 Impact factor: 9.867
Authors: P Balermpas; F Rödel; R Liberz; J Oppermann; J Wagenblast; S Ghanaati; P N Harter; M Mittelbronn; C Weiss; C Rödel; E Fokas Journal: Br J Cancer Date: 2014-08-05 Impact factor: 7.640